entecavir, lamivudine
ApprovedSmall molecule
entecavir, lamivudine is one of 9 small molecule programs targeting Lactic Acidosis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Lactic Acidosis
#DrugCompanyPhaseTrials
1Ziagen
GSKApproved
Zerit
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Avicel
SSanthera Pharmaceuticals
Phase 2
entecavir, lamivudine
AAsan Medical Center
Approved
Riboflavin
CCornea and Laser Eye Institute
Phase 2
Thiamine
UUniversiti Kebangsaan Malaysia Medical Centre
Phase 2
Sodium Dichloroacetate
UUniversity of California, San Diego
Phase 3
IW-6463
TTisento Therapeutics
Phase 2
Dichloroacetate
SSaol Therapeutics Inc
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lactic Acidosis1 trial
Lactic Acidosis During Entecavir(ETV)Treatment
Terminated·—·Phase 4·NCT01354652·5 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for entecavir, lamivudine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAsan Medical Center